Cost-Effectiveness of Donanemab for Early Alzheimer’s Disease in Australia – The Medical Journal of Australia

When Australia’s Therapeutic Goods Administration approved donanemab for early Alzheimer’s disease in May 2025, it marked a pivotal moment in dementia care—a treatment proven to slow cognitive decline but accompanied by significant safety considerations and system readiness challenges. While this development unfolded halfway across the globe, its implications resonate deeply within American communities grappling with similar demographic pressures, particularly in metropolitan areas like Seattle, Washington, where aging populations intersect with innovation-driven healthcare ecosystems. The conversation isn’t merely about a new drug; it’s about how local systems adapt when breakthrough therapies demand unprecedented coordination between neurology specialists, infusion centers, and caregiver support networks—a reality acutely felt in neighborhoods from Ballard to Bellevue.

The core tension highlighted in Australia’s evaluation—weighing donanemab’s modest cognitive benefits against risks like amyloid-related imaging abnormalities (ARIA) and substantial financial burdens—mirrors ongoing debates in U.S. Neurology circles. Seattle, home to institutions like the University of Washington Medicine Memory and Brain Wellness Center and the Kaiser Permanente Washington Health Research Institute, has long been at the forefront of Alzheimer’s research and clinical trials. Yet approval of therapies like donanemab exposes systemic gaps: infusion capacity constraints at facilities such as Swedish Medical Center’s Cherry Hill campus, the need for specialized MRI monitoring protocols to detect ARIA, and the often-overlooked burden on family caregivers navigating complex treatment schedules. These aren’t abstract concerns; they translate to real-world trade-offs for Seattle residents weighing whether pursuing such treatments aligns with their goals of care, especially when societal costs—including lost productivity and informal caregiving hours—were found to substantially influence cost-effectiveness analyses from both healthcare system and broader perspectives.

Delving deeper reveals second-order effects that extend beyond clinical settings. In a city where tech industry growth has historically attracted younger workers, the rising prevalence of early-onset Alzheimer’s cases presents unique workplace challenges. Employers in Seattle’s South Lake Union corridor, for instance, may face increased requests for flexible accommodations as employees balance caregiving responsibilities with demanding careers in biotech or software development. Simultaneously, the emphasis on early detection—critical for donanemab’s efficacy—amplifies the importance of accessible cognitive screening services in community health centers across King County, particularly in underserved areas like South Seattle or Rainier Valley where barriers to timely diagnosis persist. This creates a ripple effect: greater demand for neuropsychologists trained in differentiating normal aging from pathological decline, heightened need for social workers versed in dementia care navigation, and ongoing pressure on transportation services like King County Metro to accommodate patients requiring frequent infusions at specialized centers.

Given my background in analyzing healthcare policy impacts on urban communities, if this trend impacts you in Seattle, here are three types of local professionals you need to understand when evaluating Alzheimer’s treatment options:

• Dementia Care Navigators with Health System Expertise: Seek professionals embedded within major Seattle healthcare systems (like Virginia Mason Franciscan Health or UW Medicine) who understand both clinical pathways and insurance intricacies. They should demonstrate specific experience coordinating amyloid-targeting therapies, including pre-authorization processes for infusions, scheduling logistics for mandatory MRI monitoring, and knowledge of local infusion center capacities—not just general dementia support.
• Neuropsychologists Specializing in Early Detection Protocols: Look for practitioners affiliated with academic medical centers or research institutions who utilize validated, culturally sensitive assessment tools appropriate for Seattle’s diverse population. Key criteria include familiarity with fluid biomarker interpretation (where applicable), experience discussing risk-benefit profiles of disease-modifying therapies with patients and families, and connections to longitudinal studies like those conducted through the Adult Changes in Thought (ACT) study at Kaiser Permanente Washington.
• Caregiver Support Coordinators with Employer Liaison Training: Prioritize individuals or programs that bridge healthcare and workplace needs, particularly those familiar with Seattle’s specific labor landscape. Effective coordinators understand Washington State’s Family Abandon Act provisions, can facilitate conversations with major local employers (including tech giants and healthcare providers) about accommodations, and maintain updated directories of respite care options accessible via public transit or offering sliding-scale fees—critical factors given the societal cost burdens highlighted in economic evaluations.

Ready to find trusted professionals? Browse our complete directory of top-rated alzheimers care experts in the seattle area today.